Gosta Labs completes €7.5M seed to scale its AI OS for oncology worldwide

November 27, 2025 at 06:00 AM UTC
Tech.eu
Original: EN
Gosta Labs completes €7.5M seed to scale its AI OS for oncology worldwide

Helsinki-based healthtech firm Gosta Labs secured €7.5 million in seed funding to scale its AI operating system designed for oncology. This investment round, led by Voima Ventures, underscores the growing interest in AI-driven solutions within the complex field of cancer care and the potential for European companies to lead in this area. Gosta Labs aims to revolutionize cancer treatment through advanced digital tools. The AI operating system developed by Gosta Labs converts patient visits into structured data, summarizes patient journeys, and automates clinical documentation. The system also assesses key clinical parameters for each treatment pathway, linking decisions to international guidelines and aiding oncologists. Preliminary results presented at the ESMO 2025 Congress showed that the system generates high-quality consultation notes in real-time, reducing documentation time to under two minutes. This technology directly impacts oncologists, enabling them to deliver faster, more consistent care by reducing administrative burdens and freeing up time for patient interaction. The AI platform also aims to improve the quality of care by providing a structured view of patient data, aiding in more informed and personalized treatment decisions. The funding will support Gosta Labs in expanding its reach globally and enhancing its medical-device-grade product. Founded in 2023 by the founders of Kaiku Health, Gosta Labs leverages their experience in developing regulated digital health solutions. With this new investment, the company is poised to further develop its technology and make a significant impact on cancer treatment worldwide, contributing to European digital health innovation.

To provide multilingual access, this article summary was automatically generated.

Source Information

Publication: Tech.eu
Published: November 27, 2025 at 06:00 AM UTC
All rights remain with the original publisher.